A promising new Alzheimer's drug may assist spell "the beginning of the end" for the neurodegenerative illness.

US pharmaceutical large Eli Lilly will announce the complete scientific trial outcomes for its Alzheimer's drug donanemab at a convention in Amsterdam as we speak.

The drug, which is taken as a month-to-month infusion into the bloodstream for 18 months, was found to slow mental decline by 36% in section 3 trials, the corporate introduced in May.

It works by focusing on and eradicating clusters of the protein amyloid within the mind.

Analysis: Drug gives hope, however stays out of attain in UK

The NHS is nowhere close to prepared to supply the primary efficient Alzheimer's medication to the massive numbers of people that want them.

Estimates by Alzheimer's Research UK recommend 575,000 folks within the UK would meet the therapy standards used within the scientific trials of lecanemab and donanemab.

These medication work finest when given on the very first phases of Alzheimer's, or earlier nonetheless when sufferers have what docs name gentle cognitive impairment.

But that wants a analysis the NHS simply cannot ship on the scale wanted.

Read Thomas Moore's analysis here.

"After 20 years with no new Alzheimer's disease drugs in the UK, we now have two potential new drugs in 12 just months," Dr Richard Oakley, affiliate director on the Alzheimer's Society, wrote in The Mirror.

"This could be the beginning of the end for Alzheimer's disease."

It comes after trials confirmed one other drug known as lecanemab slowed development of Alzheimer's signs by 27% in sufferers within the early phases of the illness. The drug was approved for use in the US earlier this month.

After the outcomes of the donanemab trial are launched, specialists all over the world will research the findings to look at the advantages of the drug and whether or not they outweigh the chance of unwanted side effects.

Such threat elements may embrace mind swelling and bleeding.

Regulators within the UK would wish to evaluate the drug to resolve whether or not to licence it as secure - a course of that might take between 12 and 18 months - then the NHS would resolve which sufferers it may be prescribed to based mostly on cost-effectiveness.

Estimates recommend the medication may assist 720,000 folks, in response to the Alzheimer's Society and Alzheimer's Research UK, together with 286,000 with gentle Alzheimer's and 435,000 with gentle cognitive impairment, which is a precursor to the illness.

Is UK prepared for brand spanking new Alzheimer's medication?

However, docs beforehand warned hundreds of sufferers within the UK could miss out on the advantages if such medication turn out to be accessible resulting from an absence of mind scanners and specialist clinics.

Amyloid plaques might be detected by taking a pattern of spinal fluid or by a PET scan, of which there are round 86 scanners within the UK.

Click to subscribe to the Sky News Daily wherever you get your podcasts

Around 850,000 folks in Britain have Alzheimer's illness, which is the most typical type of dementia.

It causes gentle reminiscence loss and might significantly have an effect on an individual's skill to hold out strange day by day actions.